These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 16163667)

  • 1. Correlations between genotype and pharmacological, histological, functional, and clinical phenotypes in malignant hyperthermia susceptibility.
    Monnier N; Kozak-Ribbens G; Krivosic-Horber R; Nivoche Y; Qi D; Kraev N; Loke J; Sharma P; Tegazzin V; Figarella-Branger D; Roméro N; Mezin P; Bendahan D; Payen JF; Depret T; Maclennan DH; Lunardi J
    Hum Mutat; 2005 Nov; 26(5):413-25. PubMed ID: 16163667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ryanodine receptor mutations in malignant hyperthermia and central core disease.
    McCarthy TV; Quane KA; Lynch PJ
    Hum Mutat; 2000; 15(5):410-7. PubMed ID: 10790202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiminicore disease in a family susceptible to malignant hyperthermia: histology, in vitro contracture tests, and genetic characterization.
    Guis S; Figarella-Branger D; Monnier N; Bendahan D; Kozak-Ribbens G; Mattei JP; Lunardi J; Cozzone PJ; Pellissier JF
    Arch Neurol; 2004 Jan; 61(1):106-13. PubMed ID: 14732627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores.
    Quane KA; Keating KE; Healy JM; Manning BM; Krivosic-Horber R; Krivosic I; Monnier N; Lunardi J; McCarthy TV
    Genomics; 1994 Sep; 23(1):236-9. PubMed ID: 7829078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild clinical and histopathological features in patients who carry the frequent and causative malignant hyperthermia RyR1 mutation p.Thr2206Met.
    Rueffert H; Wehner M; Ogunlade V; Meinecke C; Schober R
    Clin Neuropathol; 2009; 28(6):409-16. PubMed ID: 19919814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing the number of diagnostic mutations in malignant hyperthermia.
    Levano S; Vukcevic M; Singer M; Matter A; Treves S; Urwyler A; Girard T
    Hum Mutat; 2009 Apr; 30(4):590-8. PubMed ID: 19191329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genotype-phenotype comparison of the Swiss malignant hyperthermia population.
    Girard T; Urwyler A; Censier K; Mueller CR; Zorzato F; Treves S
    Hum Mutat; 2001 Oct; 18(4):357-8. PubMed ID: 11668625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic analysis with calcium-induced calcium release test in Japanese malignant hyperthermia susceptible (MHS) families.
    Maehara Y; Mukaida K; Hiyama E; Morio M; Kawamoto M; Yuge O
    Hiroshima J Med Sci; 1999 Mar; 48(1):9-15. PubMed ID: 10213958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Biology of malignant hyperthermia: a disease of the calcium channels of the skeletal muscle].
    Monnier N; Lunardi J
    Ann Biol Clin (Paris); 2000; 58(2):147-56. PubMed ID: 10760701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutations in RYR1 in malignant hyperthermia and central core disease.
    Robinson R; Carpenter D; Shaw MA; Halsall J; Hopkins P
    Hum Mutat; 2006 Oct; 27(10):977-89. PubMed ID: 16917943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minicore myopathy with ophthalmoplegia caused by mutations in the ryanodine receptor type 1 gene.
    Jungbluth H; Zhou H; Hartley L; Halliger-Keller B; Messina S; Longman C; Brockington M; Robb SA; Straub V; Voit T; Swash M; Ferreiro A; Bydder G; Sewry CA; Müller C; Muntoni F
    Neurology; 2005 Dec; 65(12):1930-5. PubMed ID: 16380615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A case of discordance between genotype and phenotype in a malignant hyperthermia family.
    Fortunato G; Carsana A; Tinto N; Brancadoro V; Canfora G; Salvatore F
    Eur J Hum Genet; 1999; 7(4):415-20. PubMed ID: 10352931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic detection of susceptibility to malignant hyperthermia in Belgian families.
    Heytens L
    Acta Anaesthesiol Belg; 2007; 58(2):113-8. PubMed ID: 17710899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant hyperthermia and central core disease causative mutations in Swedish patients.
    Broman M; Islander G; Müller CR; Ranklev-Twetman E
    Acta Anaesthesiol Scand; 2007 Jan; 51(1):50-3. PubMed ID: 17081152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the diagnosis of malignant hyperthermia susceptibility: how confident can we be of genetic testing?
    Robinson RL; Anetseder MJ; Brancadoro V; van Broekhoven C; Carsana A; Censier K; Fortunato G; Girard T; Heytens L; Hopkins PM; Jurkat-Rott K; Klinger W; Kozak-Ribbens G; Krivosic R; Monnier N; Nivoche Y; Olthoff D; Rueffert H; Sorrentino V; Tegazzin V; Mueller CR
    Eur J Hum Genet; 2003 Apr; 11(4):342-8. PubMed ID: 12700608
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [What significance to genotype changes have in diagnosis of malignant hyperthermia?].
    Steinfath M; Scholz J; Singh S; Wappler F
    Anasthesiol Intensivmed Notfallmed Schmerzther; 1996 Aug; 31(6):334-43. PubMed ID: 8962927
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional properties of RYR1 mutations identified in Swedish patients with malignant hyperthermia and central core disease.
    Vukcevic M; Broman M; Islander G; Bodelsson M; Ranklev-Twetman E; Müller CR; Treves S
    Anesth Analg; 2010 Jul; 111(1):185-90. PubMed ID: 20142353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree.
    Brown RL; Pollock AN; Couchman KG; Hodges M; Hutchinson DO; Waaka R; Lynch P; McCarthy TV; Stowell KM
    Hum Mol Genet; 2000 Jun; 9(10):1515-24. PubMed ID: 10888602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Current aspects of the diagnosis of malignant hyperthermia].
    Rüffert H; Olthoff D; Deutrich C; Froster UG
    Anaesthesist; 2002 Nov; 51(11):904-13. PubMed ID: 12434264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central core disease is due to RYR1 mutations in more than 90% of patients.
    Wu S; Ibarra MC; Malicdan MC; Murayama K; Ichihara Y; Kikuchi H; Nonaka I; Noguchi S; Hayashi YK; Nishino I
    Brain; 2006 Jun; 129(Pt 6):1470-80. PubMed ID: 16621918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.